- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05888727
Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis
Feasibility and Initial Efficacy of a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis
The goal of this randomized controlled clinical trial is to examine the feasibility and initial efficacy of undertaking and delivering a novel, stakeholder-informed exercise training program for wheelchair users with multiple sclerosis. The main questions it aims to answer are:
- Is the study feasible as measured by participant recruitment (24 participants total), retention (80%), and safety (adverse events)?
- Is the study acceptable as measured by participant satisfaction and perceptions using an evaluation survey and semi-structured interviews?
- Is there significant change in following the 16-week study in metabolic health outcomes, MS symptoms, and exercise behavior change? Participants will be randomized to complete the 16-week SPIN exercise training program or WellMS attention/contact wellness program.
Researchers will compare the SPIN and WellMS groups to determine if there is a significant difference in metabolic health outcomes, MS symptoms, and exercise behavior change.
Study Overview
Status
Conditions
Detailed Description
The proposed study will use a randomized controlled design to examine the feasibility and initial efficacy of undertaking and delivering a novel, stakeholder-informed exercise training program for wheelchair users with MS compared with an attention/contact wellness control condition. Feasibility testing is essential for (a) learning if an intervention can be delivered and then (b) refining the approach before conducting an expensive, fully powered efficacy study. The primary outcome of interest is process and resource feasibility as measured by participant recruitment, retention, and safety. The secondary outcome of interest is acceptability, specifically participant satisfaction and perceptions, assessed through an evaluation survey and semi-structured interviews. The tertiary outcomes encompass scientific outcomes of interest for larger efficacy trials (i.e., metabolic health outcomes, MS symptoms, and exercise behavior change).
Twenty-four participants will be recruited and randomized to complete the 16-week SPIN exercise training program or WellMS attention/contact wellness program. Recruitment, screening, and enrollment will be completed by a graduate research assistant and the intervention will be delivered online by the PI through one-on-one behavioral coaching. Data regarding the primary, secondary, and tertiary outcomes will be collected at throughout the study period.
The proposed study includes three specific aims and hypotheses:
Specific Aim 1: Evaluate the feasibility (i.e., recruitment, retention, and safety) of an exercise training intervention and attention/contact wellness control condition delivered over a 16-week period in a sample of 24 adult wheelchair users with MS from the Dallas-Fort Worth Metroplex.
Hypothesis 1: The study protocol will be feasible in terms of reaching recruitment goals (n=24; 12 per group) within a one-year period, retaining 80% or more of those participants through the full 16-week study period, and safe in terms of <10% of participants reporting adverse events.
Specific Aim 2: Evaluate the acceptability (i.e., participant satisfaction and perceptions) of a 16-week exercise training intervention and attention/contact wellness control condition in a sample of 24 adult wheelchair users with MS from the Dallas-Fort Worth Metroplex.
Hypothesis 2: Participants in both conditions will report high satisfaction (mean rating 4/5 or greater) via formative evaluation surveys and positive perceptions regarding their assigned program via post-test interviews.
Specific Aim 3: Assess the scientific outcomes of interest (i.e., metabolic health, MS symptoms, and exercise behavior change) for determining effect size and sample size estimates in powering a future R01.
Hypothesis 3: The intervention exercise training program will lead to greater improvements in metabolic health outcomes (i.e., HbA1c, cholesterol, glucose, and triglycerides, MS symptoms (i.e., fatigue, pain, depression, and quality of life) and exercise behavior compared to the attention/control wellness program.
Procedures. All study procedures have been reviewed and approved by the University of North Texas Institutional Review Board. Interested participants will contact the graduate research assistant for a telephone screening, which includes a comprehensive description of the study followed by screening for inclusion criteria. Participants deemed eligible for the study will then be sent a consent form to review and sign using through DocuSign. When the graduate research assistant receives the signed consent form, participants will be mailed a pre-test/baseline assessment packet. The pre-test assessment packet will include Actigraph GT3X+ accelerometer and instructions to wear the accelerometer on the non-dominant wrist for 7 days as well as an order for blood sample collection at a Quest Diagnostics location that is convenient for them. Participants will complete a battery of questionnaires online using Qualtrics. When the graduate research assistant receives the accelerometer and notification that a blood sample has been collected, participants will be randomized using a random numbers sequence with concealed allocation (i.e., opaque sealed envelopes) by a member of the research team. Following randomization, participants will be mailed their condition-specific program materials as well as instructions for downloading Zoom. Participants will be provided an opportunity to complete technology training sessions prior to beginning the program to support individuals with limited digital literacy. Further, the research team will have 3 data-enabled devices for participants who lack hardware and/or Internet access. Post-test assessment of tertiary outcomes following the 16-week intervention will mirror baseline assessments. Participants will be asked to complete an additional evaluation questionnaire to assess satisfaction with the program and usability of intervention components. All participants will be invited to complete a post-test semi-structured interview via Zoom to provide feedback on their experiences and suggestions for refining the program. All participants will be compensated for completing each assessment, and an additional sum will be provided for those who complete the post-test interview.
Data Analyses. The analysis will use the intent-to-treat principle where participants will be analyzed in their randomization assignment. The focus of Specific Aims 1 & 2 is on feasibility of the study protocol. Descriptive statistics including frequencies and percentages will be used to assess Hypotheses 1 & 2. Hypothesis 2 is focused on equally favorable outcomes between conditions, which is important for guiding a future, larger efficacy study because if one condition is rated more favorably that would incorporate additional bias. If differences in feedback are identified, modifications to the appropriate condition will be made prior to fully-powered efficacy testing. The scientific outcomes in Hypothesis 3 (i.e., metabolic health outcomes, MS symptoms, and exercise behavior) will be examined using 2 time by 2 group mixed factor ANOVA with estimation of Cohen's d values for effect sizes. Participant's change in scientific outcomes will be further examined and compared with the >0.5 SD will be considered meaningful change based on benchmarks established in previous research.
Fidelity Monitoring. The research team is creating a fidelity monitoring protocol that aligns with the 5 domains outlined by the NIH Behavior Change Consortium adapted from a protocol led by the PI that was applied in a Phase-III clinical trial. The PI will serve as the behavioral coach given her experience as a behavioral coach in both physical activity and wellness conditions in 5 waves of the aforementioned clinical trial. The PI is not involved in outcome assessments and parallel scripts have been developed for each condition oriented toward the condition's content. The scripts include a check-in on the previous week, discussion of the week's Newsletter topic, and planning for the subsequent week. In line with our previous studies, randomly selected participant chats will be selected for fidelity monitoring to be completed; a Co-I will review the recorded session using a standard checklist to ensure systematic bias is not present.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- diagnosis of MS
- self-reported use of a wheelchair (i.e., manual wheelchair, power wheelchair, or scooter) >50% of the time
- age of 18 years or older
- relapse free for the past 30 days
- being non-active defined as not engaging in regular physical activity (30 minutes accumulated per day) on more than 2 days of the week during the previous 6 months (i.e., not meeting current physical activity guidelines for MS)
Exclusion Criteria:
- during telephone screening participants will complete an exercise pre-participation health screen and if participants report any symptoms or conditions contradictive of exercise then physician clearance will be required before enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise Training Intervention
|
The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS.
The 16-week program includes one-on-one video chats with a behavioral coach and various "tracks" for progressive increases in both strength and aerobic training.
The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair.
The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users.
Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity.
The research team created 12 Newsletters that align with 12 proposed coaching calls.
|
|
Active Comparator: Wellness Control
|
The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing).
This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240).
The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS).
The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention.
All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition.
Participants will be provided with a participant manual, logbook, and calendar.
Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Study Feasibility: Number of Participants Recruited
Time Frame: 16-weeks
|
Feasibility of the intervention will be measured based on reaching recruitment goals (n=24) within a one-year period.
|
16-weeks
|
|
Study Feasibility: Number of Participants Retained
Time Frame: 16-weeks
|
Feasibility of the intervention will be measured based on retention of >80% of enrolled participants for the full 16-week study period.
|
16-weeks
|
|
Study Feasibility: Number of Participants With Study-Related Adverse Events
Time Frame: 16-weeks
|
16-weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability: Number of Participants With Positive Perceptions During Semi-Structured Interview
Time Frame: 16-weeks
|
Acceptability was assessed through semi-structured interviews conducted with participants.
Positive perception was defined as participants expressing favorable views or satisfaction with the intervention.
Reported is the number of participants who expressed positive perceptions during the interview.
|
16-weeks
|
|
Acceptability as Measured by the Post-intervention Acceptability Survey
Time Frame: 16-weeks
|
The post-intervention acceptability Survey total score ranges from 1 to 5, a higher score indicates greater acceptability.
|
16-weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Metabolic Health Outcomes: Triglycerides
Time Frame: 16-weeks
|
Triglycerides will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community.
Participants will complete blood sample collection at baseline and 16 weeks.
|
16-weeks
|
|
Change in Metabolic Health Outcomes: HbA1c
Time Frame: 16-weeks
|
HbA1c will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community.
Participants will complete blood sample collection at baseline and 16 weeks.
|
16-weeks
|
|
Change in Metabolic Health Outcomes: Cholesterol
Time Frame: 16-weeks
|
Cholesterol levels will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community.
Participants will complete blood sample collection at baseline and 16 weeks.
|
16-weeks
|
|
Change in Metabolic Health Outcomes: Glucose
Time Frame: 16-weeks
|
Fasting glucose will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community.
Participants will complete blood sample collection at baseline and 16 weeks.
|
16-weeks
|
|
Change in MS Symptoms: Fatigue
Time Frame: 16-weeks
|
Fatigue will be assessed using the Fatigue Severity Scale.
Fatigue Severity Scale scores range from 9-63, with higher scores indicating greater fatigue.
Participants will complete this questionnaire at baseline and 16 weeks.
|
16-weeks
|
|
Change in MS Symptoms: Pain
Time Frame: 16-weeks
|
Pain will be assessed using the McGill Pain Questionnaire-Short Form.
McGill Pain Questionnaire-Short Form scores range from 0-45, with higher scores indicating greater pain.
Participants will complete this questionnaire at baseline and 16 weeks.
|
16-weeks
|
|
Change in MS Symptoms: Depression
Time Frame: 16-weeks
|
Depressive symptoms will be assessed using the Hospital Anxiety and Depression Scale.
Hospital Anxiety and Depression Scale depression subscale scores range from 0-21, with higher scores indicating greater depressive symptoms.
Participants will complete this questionnaire at baseline and 16 weeks.
|
16-weeks
|
|
Change of Physical Activity Levels Through the Godin Leisure-Time Exercise Questionnaire
Time Frame: 16-weeks
|
Physical activity will be assessed using the Godin Leisure-Time Exercise Questionnaire.
Total Godin Leisure Time Exercise Questionnaire scores range from 0-119, with higher scores indicating more exercise behavior.
Participants will complete this questionnaire at baseline and 16 weeks.
|
16-weeks
|
|
Adherence to Assigned Condition
Time Frame: 16-weeks
|
We will ask all participants to complete a weekly form in an individual REDCap portal with the information from their logbook as an additional measure of adherence to the exercise training or wellness program (i.e., behavior change).
|
16-weeks
|
|
Change in MS Symptoms: Quality of Life
Time Frame: 16-weeks
|
Quality of life will be assessed using the 12-item Short Form Survey.
The 12-item Short Form Survey scores include mental and physical component subscale scores, which each range from 0-100, with higher scores indicating greater quality of life.
Participants will complete this questionnaire at baseline and 16 weeks.
|
16-weeks
|
|
Change of Physical Activity Levels Through Accelerometery From Baseline at 16 Weeks
Time Frame: 16-weeks
|
Physical activity will be assessed using an ActiGraph accelerometer.
Participants will wear an accelerometer on a wristband on their nondominant wrist during the waking hours of a 7 day period.
Participants will complete this at baseline and 16 weeks.
|
16-weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Stephanie L Silveira, PhD, The University of Texas Health Science Center, Houston
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-SPH-23-0719
- R03HD107615 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Seated Physical activity INtervention for persons with MS, "SPIN" program- Intervention Condition
-
University of Alabama at BirminghamCompletedMultiple Sclerosis (MS)United States
-
Georgia Institute of TechnologyUniversity of Georgia; University of Illinois at Urbana-Champaign; National Institute... and other collaboratorsCompletedAging | Disability PhysicalUnited States
-
University of Alabama at BirminghamCompletedMultiple SclerosisUnited States
-
University Hospital, CaenCompletedCoronary Artery Disease | MotivationFrance
-
University of Illinois at ChicagoEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingMultiple SclerosisUnited States
-
University of Missouri-ColumbiaEnrolling by invitation
-
The Miriam HospitalCompleted
-
Federal University of BahiaCompletedThe INFLUENCE of PHYSICAL ACTIVITY on the HEALTH and WELL-BEING of BREAST CANCER SURVIVORS (PAF-SBM)Breast Cancer SurvivorBrazil
-
Bahçeşehir UniversityCompleted
-
Mayo ClinicCompletedMalignant Solid Neoplasm | Lymphoma | Multiple Myeloma | Hematopoietic and Lymphoid System Neoplasm | Chronic LeukemiaUnited States